Anti-HGF monoclonal antibody L2G7

Drug Profile

Anti-HGF monoclonal antibody L2G7

Alternative Names: Anti-HGF mAb L2G7; HuL2G7; L2G7; TAK-701

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Galaxy Biotech LLC
  • Developer Galaxy Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Hepatocyte growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 Jul 2012 Anti-HGF monoclonal antibody L2G7 is available for licensing as of 31 Jul 2012. http://www.galaxybiotech.com
  • 31 Jul 2012 Anti-HGF monoclonal antibody L2G7 is no longer licensed to Takeda
  • 19 Jun 2012 Takeda to terminate its license to Anti-HGF monoclonal antibody L2G7
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top